The General Hospital Corporation

Massachusetts Institute of Technology

Aalborg University

Naar, Anders M.

Rajurkar, Mihir Shivadatta

David T Ting

Daniel Arie Haber

Shyamala Maheswaran

Robert Samuel Langer

Elazer Reuven Edelman

Anders M Naar

Andreas Petri

Sakari Kauppinen

Jeffrey W Clark

Cristina Rosa Annamaria Ferrone

Matteo Ligorio

Francesca Bersani

Laura Indolfi

Doron Lipson

Robert S Langer, Jr

Mihir Shivadatta Rajurkar

Robert S Langer

Cristina Rosa Ferrone

Elazer R Edelman

Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides.

Targeting human satellite II (HSATII)

Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 &#x3bc;m to about 1000 &#x3bc;m, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.

Local drug delivery devices and methods for treating cancer

Methods for diagnosing cancer based on detecting the presence of increased levels of expression of satellite repeats and/or Line-1.

Biomarkers of cancer

The technology described herein relates to methods of detecting circulating tumor cells (CTCs), e.g. by detecting changes in the expression of certain CTC marker genes. Aberrant expression of CTC marker genes, e.g. changes in expression indicative of CTCs can also be targeted in order to treat cancer.

Methods and assays relating to circulating tumor cells

Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic HSATII satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3D culture. Induction of HSATII RNA, either in xenografts or using in vitro reconstitution models, suggests the appearance of complementary DNA intermediates.

Methods of isolating, enriching, capturing, identifying, or detecting the presence of, cancerous cells in a sample, e.g., a blood sample from a subject, by detecting the presence of one or more cancer cell surface markers selected from the group consisting of cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11, CDH17, CDH19, protocadherin 9 (PCDH9) and/or PCDH beta 13 (PCDHb13), and optionally an additional cancer cell surface marker, e.g., EpCAM, MUC1, EphB4, EGFR, CEA, and/or HER2.

Cadherins as cancer biomarkers

Growing community of inventors

Dover, MA, United States of America

David T Ting